AR062

AR062

AR062

Back to Pipeline

> R&D > Pipeline > AR062

Back to Pipeline

AR062 (anti-CD39) antibody: Prevents suppression of antitumor immune response by regulating adenosine triphosphate (ATP) metabolism in the tumor microenvironment (TME)

Prevention of anti-cancer immune suppression by regulating ATP metabolism in the tumor microenvironment (TME).

• Efficacy of AR062 via inhibition of ATP hydrolysis (SK-MEL-28, MOLP-8 cells) and T-cell proliferation

In Vitro Efficacy

In Vitro Efficacy

Effective inhibition of ATP hydrolysis and activation of T cell proliferation suppressed by adenosine

Effective inhibition of ATP hydrolysis and activation of T cell proliferation suppressed by adenosine

Effective inhibition of ATP hydrolysis and activation of T cell proliferation suppressed by adenosine

• Antitumor efficacy confirmed in tumor-bearing mouse model (Tumor Growth Inhibition, TGI) 64.7%

In Vitro Efficacy

In Vitro Efficacy

Remix Template

Remix Template

Remix Template